Please find below some recent articles published by us
Düsseldorf, 17 July 2026 – NOVACOS has provided Ardian with comprehensive advice on pharmaceutical law and regulatory matters in connection with the sale of its majority stake in the GBA Group (“GBA”), an international provider of life sciences and laboratory analytics services, to Bridgepoint. Milbank LLP led the transaction on …
Effective from December 13, 2024, the new General Product Safety Regulation (GPSR) (EU) 2023/988 will replace outdated national laws and the General Product Safety Directive (2001/95/EC), introducing harmonized rules across all EU member states. This regulation represents a significant enhancement of general product safety legislation and is set to impact …
In a nutshell, the Commission´s proposal of a new Product Liability Directive implements rather extensive rules presuming defectiveness of the product and/or the causal link between its defectiveness and the damage for the benefit of the claimants. In addition, disclosure obligations for defendants are implemented to ease the position of …
Düsseldorf. The term “hypoallergenic” is used today for a wide range of consumer products, from plasters to cosmetics to baby food. Now the highest court has ruled: The statement “hypoallergenic” does not mean that a product is completely free of allergenic ingredients. Rather, consumers correctly assume that only fewer of …
Our partner Dr. Marc Oeben holds the lecture “National Pharmaceutical Liability Law III – Practical Implementation and International Pharmaceutical Liability Law” as part of the additional qualification in pharmaceutical law at the Philipps University of Marburg. With the additional qualification in pharmaceutical law, the Faculty of Law at the Philipps …
Düsseldorf, 9 March 2021 – NOVACOS has advised investment firm Triton Fund V alongside De Brauw Blackstone Westbroek on an agreement to invest in Bergman Clinics, one of the leading chains of independent clinics in the Netherlands, Germany and Scandinavia. This investment will be in partnership with the current shareholders …